Mr. Marc Lemieux reports

KDA GROUP ANNOUNCES PARTNERSHIP AGREEMENT WITH CHU DE QUEBEC-UNIVERSITE LAVAL FOR THE DEPLOYMENT OF MEDHERIZE

KDA Group Inc. has signed a partnership and collaboration agreement with the Centre Hospitalier Universitaire de Quebec, Universite Laval, for the deployment of its Medherize platform at Hopital du Saint-Sacrement, one of the CHU de Quebec's five hospital facilities.

The Medherize platform is already implemented at Hopital du Saint-Sacrement. This partnership aims to support breast cancer patients undergoing complex oral treatments, whose follow-up and coordination require close collaboration between hospital teams and community pharmacists. It will also serve as a springboard for expanding the solution to other hospital centers across Quebec, then throughout Canada, and eventually internationally.

Medherize enables real-time therapeutic monitoring through the integration of clinical data, including information from the Dossier Sante Quebec (DSQ), and validated clinical protocols that automate the management of adverse effects. The platform provides care teams with a shared and continuous view of each patient's treatment journey, improving coordination and overall care efficiency.

The solution will soon extend beyond breast oncology to encompass a broader range of complex treatments and specialty medications, including biotherapies, additional oncology therapies, as well as treatments for autoimmune and rare genetic diseases.

"Our Medherize solution is designed to support health care professionals in delivering optimized and personalized treatments while enhancing patients' quality of life," said Marc Lemieux, chief executive officer and chairman of the board of KDA.

Dr. Julien Clement, director of professional services and medical affairs at the CHU de Quebec, added:

"The implementation of Medherize within our institution could potentially allow our health care professionals to save time in treatment follow-up and optimize the use of our resources, to the direct benefit of our patients. Our assessment of this technology aligns with our vision of a more efficient health care system that is centred on patients' needs."

M. McNeil Caron, a patient treated at the CHU de Quebec and user of Medherize, added: "The follow-up software allows me to easily and instantly access my lab results and other helpful advice. It's very user friendly. I feel truly confident and well supported."

This partnership with the CHU de Quebec has sparked strong interest within the health care industry. Several pharmaceutical companies, as well as pharmacy chains and independent pharmacists, have already expressed their intent to adopt or promote Medherize as previously disclosed by the corporation in its press release dated Dec. 1, 2025, opening significant opportunities for KDA's business model.

Ultimately, the Medherize project will help improve patients' quality of life and support health care professionals by optimizing the management of specialty medications, a complex and critical aspect of modern health care.

About KDA Group Inc.

KDA Group is a leader in technological innovations and specialized software solutions (SaaS -- software-as-a-service) for the health care professionals' market. KDA is a corporation that offers high-quality products, and has recognized and respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the health care's digital transformation, and are available for the Canadian and international markets.

We seek Safe Harbor.